Abstracts Archive - Page 1792 of 2607 - ACR Meeting Abstracts

Abstract Number: 2899 • 2016 ACR/ARHP Annual Meeting
Impact of the Clinical Characteristics of Systemic Sclerosis in Patients Quality of Life
Joana Caetano¹, Luis Melo¹, Susana Oliveira¹ and Jose Delgado Alves^1,2, ¹Department of Medicine IV, Systemic Immunomediated Diseases Unit, Fernando Fonseca Hospital, Amadora, Portugal, ²CEDOC/NOVA Medical School, Lisbon, Portugal
Background/Purpose: Systemic sclerosis (SSc) is a rare heterogenic disease, with visceral, skin and vascular damage associated with a reduced life expectancy, disability and worsening of…
Abstract Number: 2900 • 2016 ACR/ARHP Annual Meeting
The Incidence and Prevalence of Systemic Sclerosis in Northwestern Part of Turkey
Omer Nuri Pamuk¹, Mehmet Ali Balci², Salim Donmez³ and Gulsum Emel Pamuk⁴, ¹Rheumatology, Department of Rheumatology, Trakya University Medical Faculty, Edirne, Turkey, Edirne, Turkey, ²Rheumatology, Trakya University Medical Faculty, Edirne, Turkey, ³PsART study group, Ankara, Turkey, ⁴Hematology, Trakya University Medical Faculty, Edirne, Turkey
Background/Purpose: Systemic sclerosis (SSc) is a multisystem, chronic, autoimmune disease. In this hospital based study, we aimed to evaluate the prevalence and incidence of SSc…
Abstract Number: 2901 • 2016 ACR/ARHP Annual Meeting
SSc and the Significance of Blood Group Antigens
Zsuzsanna Fabianne¹ and Annica Nordin², ¹Rheumatology, Karolinska University Hospital, Stockholm, Sweden, ²Rheumatology, Karolinska University Hospital Solna, Stockholm, Sweden
Background/Purpose : Systemic sclerosis (SSc) is a rare disease, with a mean incidence 3.8 cases, prevalence 99 per million in Sweden. The two most important…
Abstract Number: 2902 • 2016 ACR/ARHP Annual Meeting
Preliminary Evaluation of Gastroesophageal Reflex Disease Outcome Measures in Scleroderma– Scleroderma Clinical Trials Consortium Gastrointestinal Working Group
Zsuzsanna McMahan¹, Tracy M. Frech², Guya Piemonte³, Marco Matucci-Cerinic⁴, Susanna Proudman^5,6, Veronica J. Berrocal⁷, Ron Hays⁸ and Dinesh Khanna⁹, ¹Department of Internal Medicine, Johns Hopkins University, Baltimore, MD, ²Division of Rheumatology, University of Utah, Salt Lake City, UT, ³University of Florence, Florence, Italy, ⁴Department of Medicine, Division of Rheumatology, University of Florence, Florence, Italy, ⁵Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, ⁶Discipline of Medicine, University of Adelaide, Adelaide, Australia, ⁷Div of Rheumatology, University of Michigan, Ann Arbor, MI, ⁸UCLA, Los Angeles, CA, ⁹University of Michigan, Ann Arbor, MI
Background/Purpose: Gastrointestinal tract (GIT) involvement occurs in approximately 95% of patients with systemic sclerosis (SSc). There is consensus in the Scleroderma Clinical Trials Consortium (SCTC)…
Abstract Number: 2903 • 2016 ACR/ARHP Annual Meeting
Transition of Nailfold Microangiopathy throughout Different Patterns of Microvascular Damage and Correlations with Organ Involvement in Systemic Sclerosis: A Twelve Year Follow-up
Alberto Sulli¹, Sabrina Paolino¹, Barbara Ruaro¹, Amelia Chiara Trombetta¹, Vanessa Smith², Maurizio Cutolo¹ and Carmen Pizzorni¹, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, Genova, Italy, ²Department of Rheumatology, Ghent University Hospital, Ghent University, Ghent, Belgium
Background/Purpose: Nailfold capillaroscopy is the validated technique to assess scleroderma microangiopathy, an early and dynamic event that may progress through different patterns of microvascular damage…
Abstract Number: 2904 • 2016 ACR/ARHP Annual Meeting
Rituximab in Systemic Sclerosis-Interstitial Lung Disease, a Case Series of 18 Patients
Gul Guzelant¹, Melike Melikoglu¹, Benan Musellim², Deniz Demir Yilmaz², Izzet Fresko¹, Emire Seyahi¹, Gulen Hatemi¹, Serdal Ugurlu¹ and Vedat Hamuryudan¹, ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University, Cerrahpasa Medical Faculty, Department of Pulmonary Medicine, Istanbul, Turkey
Background/Purpose: Interstitial lung disease (ILD) is a severe complication of systemic sclerosis (SSc). Immunosuppressives such as cyclophosphamide (CYC) and mycophenolate mophetil (MMF) are used in…
Abstract Number: 2905 • 2016 ACR/ARHP Annual Meeting
Predictors of Poor Hand Function in Systemic Sclerosis
Ashraf Raslan¹ and Vivien Hsu², ¹Medicine, Rutgers-RWJ Medical School, Jersey City, NJ, ²Rheumatology, RWJ Med Schl Scleroderma Prog, New Brunswick, NJ
Background/Purpose: Systemic Sclerosis (SSc) is a progressive systemic disease that can lead to variable degrees of morbidity and disability. Hand dysfunction in SSc patients [1]…
Abstract Number: 2906 • 2016 ACR/ARHP Annual Meeting
The Survival and Prognostic Factors of Patients with Systemic Sclerosis Turkish Experience
Orhan Zengin¹, Mehmet Ali Balci², Omer Nuri Pamuk², Bunyamin Kisacik¹, Salim Donmez², Mustafa Erkut Onder¹, Savas Aksoy¹ and Ahmet Mesut Onat¹, ¹Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, ²Rheumatology, Trakya University Medical Faculty, Edirne, Turkey
Background/Purpose: Systemic sclerosis (SSc) is a low-prevalence disease, characterized by fibrosis and vascular changes. It is the auto-immune rheumatic disease with the highest disease-related mortality…
Abstract Number: 2907 • 2016 ACR/ARHP Annual Meeting
Serum KL-6 Levels in Interstitial Lung Diseases (ILDs) Associated to Connective Tissue Diseases (CTDs)
Lise Moreer¹, Hilario Nunes¹, Louise Bondeelle¹, Yurdagul Uzunhan¹, Pascale Ghillani-Dalbin², Dominique Valeyre¹, Lucile Musset³ and Makoto Miyara³, ¹Pulmonary diseases department, Avicenne Hospital (AP-HP), Bobigny, France, ²Department of Immunology, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ³Department of immunology, Pitié-Salpêtrière Hospital (AP-HP), Paris, France
Background/Purpose: ILD is a frequent and potentially severe complication of CTDs. The course of ILD can be difficult to predict in this setting. The term…
Abstract Number: 2908 • 2016 ACR/ARHP Annual Meeting
Anti-Vinculin Antibodies: A Novel Biomarker in Systemic Sclerosis, and Its Association with Vascular Involvement
Yossra A Suliman¹, Suzanne Kafaja², Mohamed Alemam³, Isela Valera⁴, Walter Morales⁵, Mark Pimentel⁶ and Daniel E. Furst⁷, ¹Rheumatology and Rehabilitation dept., Rheumatology and Rehabilitation dept. Assiut university hospital, Assiut Egypt, Assiut, Egypt, ²Medicine/Rheumatology, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³Clinical Pathology and Laboratory Medicine Department, Assistant Lecturer, Qena, Egypt, ⁴UCLA, Los Angeles, CA, ⁵GI Motility Program, Research associate, Los Angeles, CA, ⁶Gastrointestinal, Cedar Sinai Medical Center, Los Angeles, CA, ⁷Division of Rheumatology, Department of Internal Medicine, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Vascular involvement has a major impact on the pathogenesis of Systemic sclerosis (SSc) and there is evidence that microvascular damage with endothelial cell activation …
Abstract Number: 2909 • 2016 ACR/ARHP Annual Meeting
Attitudes Toward Patient-Reported Outcome Instruments for the Assessment of Raynaud’s Phenomenon in Systemic Sclerosis
John Pauling^1,2, Tracy M. Frech^3,4, Michael Hughes⁵, Jessica K. Gordon⁶, Robyn T. Domsic⁷, Francesca Ingegnoli⁸, Neil J. McHugh^1,9, Sindhu R. Johnson¹⁰, Marie Hudson¹¹, Francesco Boin¹², Voon Ong¹³, Marco Matucci Cerinic¹⁴, Nezam Altorok¹⁵, Marina Scolnik¹⁶, Mandana Nikpour¹⁷, Ankoor Shah¹⁸, Janet E. Pope¹⁹, Dinesh Khanna²⁰ and Ariane L. Herrick²¹, ¹Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ²Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ³Internal Medicine, Salt Lake City VAMC, Salt Lake, UT, ⁴Internal Medicine-Division of Rheumatology, University of Utah School of Medicine, SLC, UT, ⁵Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, ⁶Rheumatology, Hospital for Special Surgery, New York, NY, ⁷Medicine - Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, ⁸Department of Rheumatology, Istituto Gaetano Pini, University of Milano, Italy, Milano, Italy, ⁹Rheumatology, Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, United Kingdom, ¹⁰Medicine, Division of Rheumatology, Toronto Western Hospital, University Health Network Pulmonary Hypertension Programme, Toronto General Hospital, Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ¹¹Department of Medicine, McGill University and Jewish General Hospital, Montreal, QC, Canada, ¹²Rheumatology, University California San Francisco, San Francisco, CA, ¹³Rheumatology, University College London Medical School, Royal Free Hospital, London, UK, London, United Kingdom, ¹⁴Department of Medicine, Division of Rheumatology, University of Florence, Italy, Florence, Italy, ¹⁵Rheumatology, University of Toledo Medical Center,, Toledo, OH, ¹⁶Rheumatology Section, Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ¹⁷Department of Medicine (St Vincent's Hospital), The University of Melbourne, Melbourne, Australia, ¹⁸Rheumatology and Immunology, Duke University Medical Center, Durham, NC, ¹⁹Monsignor Roney Bldg/Rheum, University of Western Ontario, St Joseph Health Care, London, ON, Canada, ²⁰Division of Rheumatology, University of Michigan Medical School, Ann Arbor, MI, ²¹Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: The Raynaud’s Condition Score (RCS) diary is a clinician-derived validated patient-reported outcome (PRO) instrument for assessing the frequency, duration and severity of Raynaud's phenomenon…
Abstract Number: 2910 • 2016 ACR/ARHP Annual Meeting
Work Productivity in Systemic Sclerosis and Association with Health Related Quality of Life
Kathleen Morrisroe¹, Molla Huq², Wendy Stevens³, Joanne Sahhar⁴, Susanna Proudman^5,6, Mandana Nikpour⁷ and Australian Scleroderma Interest Group, ¹Rheumatology, St Vincent's Hospital, Melbourne, Melbourne, Australia, ²Department of Medicine (Rheumatology), Melbourne University, Melbourne, Australia, ³Department of Rheumatology, St. Vincent’s Hospital Melbourne, Melbourne, Australia, ⁴Department of Rheumatology, Monash Medical Centre, Melbourne, Australia, ⁵Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, ⁶Discipline of Medicine, University of Adelaide, Adelaide, Australia, ⁷Melbourne University, Melbourne, Australia
Background/Purpose: We sought to assess work productivity, factors associated with reduced productivity, and the relationship between work productivity and health-related quality of life (HRQoL) in…
Abstract Number: 2911 • 2016 ACR/ARHP Annual Meeting
A Comparison of Gastrointestinal Disease Severity in African American and Caucasian Scleroderma Patients
Carolyn Fridley¹ and Virginia D. Steen², ¹Rheumatology, Georgetown University, Washington, DC, ²Rheumatology, Georgetown University Medical Center, Washington, DC
A Comparison of Gastrointestinal Disease Severity in African American and Caucasian Scleroderma Patients Background/Purpose: Systemic sclerosis (SSc) is a multisystem autoimmune disease. After skin involvement…
Abstract Number: 2912 • 2016 ACR/ARHP Annual Meeting
Performance of the Patient-Reported Outcomes Measurement Information System (PROMIS) 29 in Systemic Sclerosis -Associated Interstitial Lung Disease (SSc-ILD)
Caitlyn Fisher^1,2, Rajaie Namas³, Amber Young², Holly Wilhalme⁴ and Dinesh Khanna⁵, ¹Cognitive Science / Creative Writing, Beloit College, Beloit, WI, ²Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ³Department of Medicine [Division of Rheumatology], University of Michigan, Ann Arbor, MI, ⁴University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵University of Michigan, Ann Arbor, MI
Background/Purpose: PROMIS-29 is a generic health-related quality of life (HRQoL) instrument that was developed as part of the NIH Patient Reported Outcomes (PROs) Roadmap. Our…
Abstract Number: 2913 • 2016 ACR/ARHP Annual Meeting
Four Year Effects of Combined Bosentan and Iloprost Treatment on Nailfold Absolute Capillary Number, Fingertip Blood Perfusion and Clinical Status, in Systemic Sclerosis Patients
Amelia Chiara Trombetta¹, Carmen Pizzorni², Barbara Ruaro³, Sabrina Paolino³, Alberto Sulli², Vanessa Smith⁴ and Maurizio Cutolo³, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, Genova, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS A.O.U. San Martino-IST, University of Genova, Genoa, Italy, Genova, Italy, ³Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS A.O.U. San Martino-IST, University of Genova, Genoa, Italy, Genoa, Italy, ⁴Department of Rheumatology, Ghent University Hospital, Ghent University, Ghent, Belgium
Background/Purpose: In systemic sclerosis (SSc), microvascular damage progresses from capillary dilation to capillary loss and reactive angiogenesis, as detectable by nailfold videocapillaroscopy (NVC) [1]. The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].